康方生物-B(09926.HK)上半年營收增26.8%至1.63億元,研發開支增至5.95億元
格隆匯8月23日丨康方生物-B(09926.HK)公佈,截至2022年6月30日止六個月,得益於2021年8月上市的安尼可®(派安普利,PD-1)的商業化銷售,公司產品總銷售額為人民幣2.972億元,扣除分銷成本人民幣1.340億元后,收入增至截至2022年6月30日止六個月的人民幣1.631億元,相比截至2021年6月30日止六個月的人民幣1.286億元增加26.8%。
其他淨收入和收益由截至2021年6月30日止六個月的人民幣6510萬元增加至截至2022年6月30日止六個月的人民幣7600萬元,增長人民幣10.9百萬元或16.7%,這一增長主要歸因於政府補助的增加。
研發支出由截至2021年6月30日止六個月的人民幣5.635億元增加至截至2022年6月30日止六個月的人民幣5.954億元,增長人民幣3190萬元,公司對候選藥物的臨牀開發計劃進行了審查和優先排序,戰略性集中更多資源快速推進該等後期或註冊試驗階段的臨牀項目,包括AK104聯合化療治療一線胃癌、AK104聯合化療治療一線宮頸癌、AK112(PD–1/VEGF)、AK101(IL–12/IL–23)及AK102(PCSK9)多個III期項目,以及AK117(CD47)等Ib/II期項目。
截至2022年6月30日止六個月,集團銷售及市場推廣開支為人民幣1.495億元。該開支乃主要是(i)因籌建即將上市的產品卡度尼利(AK104,PD–1/CTLA–4)而發生的員工成本及營銷開支增加;及(ii)就銷售安尼可®的營銷開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.